I have a confession: for a long time, scientists looked at the dense scar-like thicket around pancreatic tumors and thought, more or less, “Aha, the villain’s hedge - rip it out.” Reasonable! If a tumor is an invasive weed, and the garden is choked with brambles, you reach for the shears. But cancer biology, being the sort of garden that hides a rake exactly where your foot will find it, turned out to be trickier.
Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, often grows inside a tough, fibrotic neighborhood called the tumor microenvironment. This isn’t just scenery. It is soil, fence, irrigation system, and occasionally a suspiciously helpful garden gnome. Cancer-associated fibroblasts help build that dense support structure, which can block drugs, confuse immune cells, and make treatment feel like trying to water a rosebush through a brick wall.
A new Nature Cancer Research Briefing highlights a phase 1 study testing whether paricalcitol, a vitamin D receptor agonist already used for kidney-related hormone problems, might help soften that tumor garden when paired with standard chemotherapy for metastatic pancreatic cancer.[1,2]
The Weeds Have a Wall
The chemotherapy backbone here was gemcitabine plus nab-paclitaxel, a familiar regimen in metastatic pancreatic cancer. The new question was not “Can paricalcitol kill every cancer cell with a heroic trumpet solo?” It was humbler and possibly more interesting: can it coax the tumor’s surrounding stroma into a less hostile state, so chemotherapy and immune cells have a better shot?
That idea comes from earlier lab work showing that vitamin D receptor signaling can push activated pancreatic stellate cells and fibroblasts toward a quieter, less wound-up state.[3] Think of fibroblasts as the garden crew. In healthy tissue, they mend fences. Around pancreatic cancer, some of them start building a thorn maze, filing permits under “Absolutely Not Helpful.”
What the Trial Actually Did
The study randomized 36 patients with previously untreated metastatic pancreatic cancer to chemotherapy plus placebo, intravenous paricalcitol, or oral paricalcitol. The main goal was safety, not proving survival benefit. That matters. Phase 1 trials are mostly about asking, “Can humans tolerate this combination without the whole watering system exploding?”
Overall, paricalcitol could be given with chemotherapy. One caution sprouted up: five of 12 patients receiving oral paricalcitol developed grade 2 to 4 hypercalcemia, meaning elevated calcium levels, and needed dose reductions.[2] Vitamin D biology does like calcium. That is its whole cottage industry.
The researchers also collected tumor biopsies before treatment and again after several weeks. Those samples are where the story gets leafy. In patients receiving paricalcitol, tumors showed fewer activated αSMA-positive fibroblasts, changes in vitamin D receptor activity, and more CD8-positive T cells sitting near tumor cells.[2] CD8 T cells are immune system pruning shears with opinions. Pancreatic tumors often keep them outside the fence, so seeing more of them in the neighborhood is a promising sign.
The Harvest Is Promising, But Small
There were hints of better treatment response. Dana-Farber reported partial responses in 10 of 24 patients receiving paricalcitol versus one of 12 receiving placebo, and five patients in the paricalcitol groups were progression-free at one year versus none in the placebo group.[4] That is the sort of result that makes researchers lean forward in their chairs, though probably not spill their coffee yet.
Why the caution? Because this trial was small and not designed to prove efficacy. It was safety-focused, with exploratory biology. Also, pancreatic cancer has humbled many clever ideas before. The compost pile of “looked great early, failed later” is unfortunately well fertilized.
Still, the biological signal matters. A 2023 review in Annual Review of Pathology describes how pancreatic tumors use stromal complexity and immune exclusion to resist therapy.[5] A 2024 Cancer Discovery review similarly frames extracellular matrix remodeling as deeply tied to whether cancer drugs can do their job.[6] This paricalcitol study fits that bigger field: don’t just poison the weed, tend the soil so treatment can reach the roots.
Why This Could Matter
If larger studies confirm these findings, paricalcitol-like strategies could become a way to make pancreatic tumors less walled-off and more treatable. That would not replace chemotherapy, immunotherapy, surgery, or targeted drugs. It would be more like opening the garden gate so the rest of the crew can finally get inside without climbing over a hedge wearing hospital clogs.
The study also raises a practical biomarker question: tumors with higher vitamin D receptor expression seemed more likely to respond in the paricalcitol arms.[2] If that holds up, doctors might one day test which tumor gardens have the right receptors before adding this kind of stromal pruning.
For now, the lesson is gentle but sturdy: sometimes the path through pancreatic cancer is not only attacking the tumor cells. Sometimes it is persuading the surrounding thicket to stop being such an overprotective, thorny little menace.
References
-
Combination of paricalcitol with chemotherapy shows promise in phase 1 study of metastatic pancreatic cancer. Nature Cancer. 2026. https://doi.org/10.1038/s43018-026-01164-9
-
Perez KJ, Dias Costa A, Jordan A, et al. Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. Nature Cancer. 2026. https://doi.org/10.1038/s43018-026-01165-8
-
Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell. 2014;159:80-93. https://doi.org/10.1016/j.cell.2014.08.007
-
Dana-Farber Cancer Institute. Vitamin D analog shuts down pancreatic cancer’s shield in clinical trial. 2026. https://www.dana-farber.org/newsroom/news-releases/2026/from-discovery-to-patient-care-vitamin-d-analog-shuts-down-pancreatic-cancers-shield-in-clinical-trial
-
Sherman MH, Beatty GL. Tumor Microenvironment in Pancreatic Cancer Pathogenesis and Therapeutic Resistance. Annual Review of Pathology. 2023;18:123-148. https://doi.org/10.1146/annurev-pathmechdis-031621-024600
-
Prakash J, Shaked Y. The Interplay between Extracellular Matrix Remodeling and Cancer Therapeutics. Cancer Discovery. 2024;14:1375-1388. https://doi.org/10.1158/2159-8290.CD-24-0002
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.